NovoCure Limited
NVCR
$17.24
$0.392.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.48% | 8.28% | 11.17% | 14.58% | 18.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.48% | 8.28% | 11.17% | 14.58% | 18.27% |
| Cost of Revenue | 17.42% | 21.29% | 15.98% | 11.78% | 7.14% |
| Gross Profit | 5.85% | 4.51% | 9.70% | 15.47% | 21.99% |
| SG&A Expenses | 6.77% | -3.11% | 15.18% | 14.02% | 10.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.10% | 4.00% | 11.48% | 9.53% | 6.85% |
| Operating Income | -11.49% | 11.49% | -12.65% | 6.07% | 22.10% |
| Income Before Tax | -34.97% | -3.88% | -31.45% | -0.66% | 24.66% |
| Income Tax Expenses | -106.30% | -100.06% | -23.08% | 4.76% | 68.16% |
| Earnings from Continuing Operations | -5.40% | 19.21% | -18.60% | -1.33% | 14.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.40% | 19.21% | -18.60% | -1.33% | 14.82% |
| EBIT | -11.49% | 11.49% | -12.65% | 6.07% | 22.10% |
| EBITDA | -9.92% | 14.28% | -11.69% | 7.04% | 23.49% |
| EPS Basic | -1.53% | 21.71% | -15.64% | 0.87% | 16.28% |
| Normalized Basic EPS | -24.50% | 3.20% | -25.22% | 0.23% | 21.19% |
| EPS Diluted | -1.53% | 21.71% | -15.64% | 0.87% | 16.28% |
| Normalized Diluted EPS | -24.50% | 3.20% | -25.22% | 0.23% | 21.19% |
| Average Basic Shares Outstanding | 3.49% | 3.32% | 2.80% | 2.30% | 1.73% |
| Average Diluted Shares Outstanding | 3.49% | 3.32% | 2.80% | 2.30% | 1.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |